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Abstract
Background . This article reviews the current results of radiofrequency application in the management of hepatocellular
carcinoma (HCC) with reference to the comparison between the different surgical modalities. Method . An electronic search
was performed for studies on the treatment of HCC. Results . Thermoablation by means of radiofrequency (RFA),
microwave coagulation therapy (MCT) and laser-induced thermotherapy (LITT) provides tumor necrosis with a low
complication rate. These methods are still not predictable and it is difficult to monitor the extent of necrosis in a real-time
manner. Combined transarterial embolization and RF ablation is a promising strategy for large HCCs. Radiofrequency-
assisted liver resection is unique and has become very popular recently because it permits parenchymal transection with
minimal blood loss. Conclusion . Many alternative techniques have been applied recently for the management of HCC but
their exact roles need to be defined by randomized studies. Advances in technology and refinements in technique may
provide an effective and predictable way to ablate liver tumors using radiofrequency devices.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most
common malignancies worldwide with an annual
occurrence of one million new cases [14]. An
etiologic association between HBV infection and the
development of HCC has been established with a
relative risk 200-fold greater than in non-infected
individuals [5].
Hepatitis C virus is also proving an important
predisposing factor for this malignancy, with an
incidence rate of 7% at 5 years and 14% at 10 years.
The prognosis depends on tumor stage and degree of
liver function, which affect the tolerance to invasive
treatments [6].
Surgical resection has generally been accepted as
the treatment of choice for HCC but new treatment
strategies have been developed nowadays including
local ablative therapies, transarterial embolization and
liver transplantation. With increasing detection of
small HCCs from screening programs for cirrhotic
patients it is foreseen that locoregional therapy will
play an important role in the near future.
Major advances have been made with radiofre-
quency energy application for ablation and bloodless
liver resection and the key questions with the future
perspectives are presented in this article.
Radiofrequency ablation (RFA)
Radiofrequency ablation (RFA) of liver tumors was
pioneered in 1993 by Rossi et al. [7]. RFA induces
deep thermal injury in hepatic tissue while sparing the
normal parenchyma. Its basic principle includes
generation of high-frequency alternating current
(400 MHz) which causes ionic agitation and conver-
sion to heat, with subsequent evaporation of intracel-
lular water which leads to coagulation necrosis. The
area of the injury depends on the size, position and
shape of electrode used.
RFA has been performed by percutaneous, laparo-
scopic or open techniques [8,9]. Percutaneous RFA
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usually is performed under sedation due to severe
pain [10]. The disadvantages of the method are
considered the inability for vascular inflow occlusion
through the percutaneous approach, and difficult
access for deep tumors located near blood vessels, or
neighboring the diaphragm or the bowel. On the other
hand, imaging of RFA performed during laparotomy
or laparoscopy is limited to ultrasound (US), while
the percutaneous approach offers the ability to use
US, magnetic resonance imaging (MRI) or computed
tomography (CT) guidance. The main indication is
recurrences after open procedures and patients with
poor performance status [11].
The electrode is placed through normal liver tissue
close to the tumor margin and guided by US. The
tissue is ablated at a temperature /908C for 512
minutes or until the impedance increases rapidly,
although multiple overlapping ablations are necessary
to completely destroy a tumor exceeding 3 cm in
diameter. At the end of RFA the ablated tissue takes
on the appearance of a lacrosse racket.
Currently, three devices are approved. RITA Med-
ical Systems produce a 50-W 460-kHz alternating
current generator with a variety of needles. Three,
four or seven retractable prongs are deployed once the
needle is positioned. A thermocouple at the tip of
each prong monitors the temperature. Radiothera-
peutics manufacture a 90-W generator with a 10-
prong deployable needle. Therapy is monitored by
measuring the impedance with power roll of when
impedance increases associated with completeness of
tissue ablation. Finally Radionics has an internal
circuit of cold water in the needle which may increase
the size of the thermal injury.
There are limitations related to the physics of the
RF process. Tissue charring causes increased impe-
dance that results in decreased energy absorption and
a smaller treated tissue volume. Although large
amounts of tissue can be ablated in vitro , the charring
and ‘heat sink phenomenon’ are difficult to overcome
[12].
Inflow occlusion by means of the Pringle maneuver
increases the size of the zone of coagulated necrosis
and enhances the likelihood of complete tumor cell
kill even if the tumor abuts a major intrahepatic blood
vessel. RFA treatment combined with vascular inflow
occlusion can also produce complete circumferential
necrosis around major vessels without damaging the
integrity of their walls. This modified method of
intraoperative RF takes advantage of the inflow
occlusion and proved superior to the standard method
in the retrospective study by Yamasaki et al. [13].
Alternative techniques based on the same concept
include angiographic balloon occlusion of the hepatic
artery of the liver segment involved with tumor [14]
and percutaneous transhepatic portal balloon occlu-
sion [15,16].
Radiographic assessment of the ablated lesion
should be delayed for 1 month following treatment
because of the inability to distinguish between ede-
matous tissue surrounding the lesion and residual
tumor early after the ablation [10]. Successful radio-
frequency ablation of lesions initially causes peritu-
moral hyperemia at the interface of the ablated and
normal tissue on postoperative CT, which is identified
by characteristic hypervascular rims with intense
contrast enhancement (Figure 1). Unlike cryoabla-
tion, in which the evolving ablated area can be
monitored by US, the hyperechoic area in RFA does
not correspond exactly to the area of tumor ablation,
nor does it indicate whether tumor ablation is
complete. Thus the extent of necrosis can be more
accurately assessed by helical CT, MRI or color
Doppler scan with bubble contrast. Spectophotome-
try is also a unique method of tissue necrosis detec-
tion, although it is not widely available.
Follow-up is done with CT scans and tumor
markers. The patient should undergo clinical evalua-
tion, serial liver tests and tumor marker determina-
tions every 3 months for 2 years [10]. Persistent non-
enhancement is seen in coagulated tissues but not in
viable tumor on delayed-opacification images (Figure
2). A CT scan performed during the first 3 months
usually demonstrates a cystic-density area that is
larger than the original tumor. Decrease in size of
this ablated zone over time is a sign of successful
treatment [17]. A gas bubble sign can be also noted,
but Mitsuzaki reported only 4 of 19 lesions being
related to abscesses [18]. On MRI local recurrence is
expressed by contrast enhancement, increase of ab-
lated lesion size, or evidence of areas showing low
signal intensity or high signal intensity on T1- and
T2-weighted images accordingly.
Using the aforementioned diagnostic tools several
studies have shown complete tumor necrosis in 80
90% of HCCs smaller than 35 cm after a single
session. Because RFA is a relatively new treatment
modality for HCC, the data in the literature are
preliminary results with short follow-up (Table I)
Rossi et al. reported their 7-year experience in treating
HCC with RF in 39 patients with tumors smaller than
3 cm, having survival rates 94 to 40% at 1 and 5 years,
respectively [19]. Curley et al., in a series of 110
patients, reported that 79 patients (72%) were alive at
a median of 19 months with 48% of them free of
disease [20].
Like other local ablative therapies, intrahepatic
recurrence of tumor is common, ranging from 20 to
49% [19,21]. However, the majority of recurrences
are new lesions that are probably related to multi-
centric carcinogenesis. Tumor recurrence often oc-
curs at the radial margins of the ablated tissue (Figure
3). Patient-to-patient variability of tumor geometry,
tissue response and location of the tumor close to
vasculature can lead to an incomplete ablation margin
and predispose to local tumor recurrence.
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RFA versus other ablative techniques
Recently, RFA has been compared with other local
ablative therapies and the data suggest that RFA may be
a superior option. The clinical trials [22,23] comparing
RFA to percutaneous ethanol injection (PEI) demon-
strate a clear advantage for RFA. Necrosis induced by
RFA is more predictable and treatment by a single
session is sufficient in most patients with small tumors.
PEI is preferable for patients with relatively advanced
liver disease and tumor located close to the hilum,
making RFA a difficult and less attractive option. The
disadvantages of PEI compared with the other local
ablative modalities and RF in particular is that the
distribution of ethanol is impeded by the presence of
intratumoral septa or tumor capsule and repeated
sessions are usually required for a better tumoricidal
effect. However, the combination of PEI and super-
selective embolotherapy makes the lesions more recep-
tive to the ethanol destroying tumor septation [24].
Tumor seeding has been reported to be one of the rare
Figure 2. Follow-up contrast-enhanced CT scan of an ablated
centrally located HCC with no signs of residual mass or recurrence.
Figure 1. Contrast-enhanced CT images. (a) A 5-cm hypervascular hepatocellula carcinoma (HCC) is identified on VIIth liver segment.
(b) Percutaneous RFA CT-guided procedure. (c) Image obtained after RFA showing necrosis of the tumor and a contrast-enhancing rim.
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complications after ethanol injection and is considered
an advantage compared with RF with an incidence of
0.61.1% [25] due to the small thickness of the needle.
Livraghi et al. [22] showed that for tumors B/3 cm,
there is a clear benefit in tumor necrosis after RFA
(90% vs 80% after PEI). A Japanese study also
demonstrated complete tumor necrosis after RFA
but only 94% after ethanol injection [23]. RFA
demands fewer treatment sessions for the same rate
of necrosis when compared with PEI [20,26,27]. The
study by Lencioni et al., apart from the benefit
concerning the percentage of tumor necrosis (91%
vs 85%), demonstrated a clear advantage in recur-
rence rate (4% vs 17%) when comparing RFA with
PEI [26]. Better survival has also been demonstrated
by Olschewski et al. [28] in a prospective randomized
study when RFA was compared with PEI.
Apart from the more predictable rate of necrosis,
the risk of tumor seeding as reported earlier seems to
be higher among patients who underwent RFA
compared with the PEI group. A biopsy-proven
needle track tumor seeding 418 months after RFA
was 12.5% in one study [29], compared with a low
incidence (0.61%) of seeding after PEI. Tumor cell
release associated with intratumoral explosion result-
ing from the increase in temperature during ablation
and the thickness of the RF needles (1518G), play
an important role in the pathogenesis of tumor
seeding [25,30].
The advantage of RFA compared with microwave
(MCT) is the need for fewer sessions. A randomized
study from Japan demonstrated similar therapeutic
results, complication rates and residual disease when
comparing the two methods, but patients who under-
went MCT needed more sessions for the same result
(2.4 vs 1.1) [31]. An experimental study showed that
RFA may be superior to MCT regarding the capacity
to produce a larger area of necrosis [32].
Although there is a lack of evidence from rando-
mized trials, conflicting data also exist from two
nonrandomized studies where cryoablation (PCS)
was compared with RFA. In the study by Pearson
et al. [33], cryotherapy was identified to have higher
complication (40.7%) and local recurrence rates
(13.6%) than radiofrequency (3.3% and 2.2%, re-
spectively). As a result, this group expressed its
preference for RF rather than cryosurgery for mana-
ging primary or metastatic liver tumors. In contrast,
Table I. Follow-up results after radiofrequency (RF) ablation therapy for HCC.
Study Number of patients Tumor size (cm) Route of RFA Necrosis (%) Recurrence (%)
Rossi et al., 1996 [21] 39 5/3 P 95 41
Rossi et al., 1998 [19] 23 5/3.5 P 100 28
Francica & Marone, 1999 [54] 15 14.3 P 90 33
Curley et al., 1999 [42] 48  P and I 100 2.1
Nicoli et al., 2000 [55] 47 16 P and I 100 
Curley et al., 2000 [20] 110 Mean 3.4 P, L, and I 95 49
Poggi et al., 2001 [56] 15 1.56.2 P 88 20
Buscarini et al., 2001 [57] 88 5/3.5 P 93 39
Elias et al., 2002 [58] 19 5/3.5 P
Kuvshinoff & Ota, 2002 [41] 11 Mean 4.0 P, L, and I 27
Adam et al., 2002 [41] 18 Mean 2.8 P 76 17
Yamasaki et al., 2002 [35] 31 5/4.0 P
Shibata et al., 2002 [31] 36 Mean 2.3 P 96 4
P, percutaneous; L, laparoscopic, I, intraoperative RF.
Figure 3. (a) Contrast-enhanced CT image of a percutaneously ablated tumor in VIth liver segment. (b) On the follow-up CT scan 9
months after RFA an enhanced mass is demonstrated at the margins of the ablated area near a dilated vessel, consistent with recurrence.
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Bilchik et al. [34] compared PCS and RFA using a
variety of approaches. Despite the similar findings in
morbidity rates, they observed no significant differ-
ences in mortality, and overall local recurrence rates
(3% vs 2.5%, and 15% vs 10%). Their analysis
identified significant differences in local recurrence
for tumors exceeding 3 cm (17% for cryotherapy vs
38% for RFA) and therefore they recommend a
tailored approach for every patient according to the
tumor’s size [34].
In a French retrospective study by Adam et al. [35],
a group of 36 patients with unresectable HCC
underwent either PCS or PRFA. There was no
statistical difference in tumor local recurrence rate
between the two methods, while similar results were
observed in the initial success rate for both treatments
(77% and 81%).
The ease of performing percutaneous RFA has also
raised the debate as regards replacement of repeat
hepatectomies as treatment of choice for tumor
recurrence. The non-invasiveness of the method, the
shorter length of hospitalization, and the lower
mortality and morbidity rates make the method quite
an attractive alternative to surgical resection [3640]
for small lesions.
As radiofrequency can be performed during open or
laparoscopic approach, or even via the percutaneous
route, a debate about the best approach is also coming
on the scene. Kuvshinoff and Ota [41] compared the
three approaches in 45 patients with HCC and
metastatic lesions, concluding that the open approach
has far superior results as regards local recurrence.
They also demonstrated that the type of tumor has a
substantial effect on overall disease-free survival. In
agreement with the findings of other studies [42,43]
they suggest that tumors B/4 cm, open approach
RFA, and concurrent hepatic resection are associated
with improved ablation site recurrence-free survival.
The laparoscopic or open approach is preferable in
patients with high risk of bleeding from coagulopathy,
large HCC /5 cm, superficial nodules adjacent to
other visceral organs or deeply located lesions not
accessible by percutaneous puncture
Indications for RFA
It is important to mention that RFA has been used for
the treatment of patients with inoperable HCC or
metastatic colorectal cancer. It is an emerging technol-
ogy that has been proposed as an alternative to
conventional PEI with similar objective response rates
and fewer sessions. The main indication is considered
patients with four or fewer liver tumors B/35 cm in
diameter. Goldberg et al. [44] have reported larger
tumors (/5 cm) treated successfully by RFA with
overlapping of the fields. Many technical innovations
such as the cool-tip electrode and portal blood flow
interruption can increase the volume of induced
coagulative necrosis to 45 cm sphere. Large HCC
(up to 6 cm in diameter) are treated alternatively by a
combination of segmental transcatheter arterial embo-
lization followed by RFA.
Complete necrosis is achieved in 65, 41 and 31% of
tumors measuring 34 cm, 45 cm and 58 cm,
respectively. The overall survival for patients with
small HCC is 94, 68 and 40% at 1, 3 and 5 years,
respectively [21]. Rossi et al. [19] have reported on an
additional 37 patients treated with RFA. In this group
there were 26 patients with HCC and 14 patients with
hepatic metastases. Although 93% showed evidence
of complete tumor ablation, 82% developed recur-
rence by 12 months of follow-up. Subsequently
Livraghi and associates [45] achieved 90% complete
necrosis of HCC B/3 cm, 71% in medium (35 cm)
and 45% in large size HCC (59 cm) with a 3-year
survival rate in Child A patients of 85%.
RFA is a well tolerated procedure with a reported
complication rate of 37% in most series. The
percutaneous approach is responsible for the largest
number of documented complications. Side effects
include mild fever, transient increase in serum trans-
aminase levels and the development of pleural effu-
sion [46]. Intraperitoneal bleeding occurs in 27% of
patients, while portal vein thrombosis has also been
reported (Figure 4). Both complications are related to
severe cirrhosis [20]. Hepatic or subcapsular hema-
toma formation or hemobilia can also occur (Figure
Figure 4. Centrally located thrombus in inferior vena cava (a) and partial thrombosis of portal vein (b), as complications of RFA treatment.
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5). Biliary complications have been noted in 1% of
patients [47]; therefore Dominique et al. have used
intraductal cooling during RF treatment for tumors
close to bile ducts [48]. RFA leaves a necrotic tissue
which is an ideal nidus for infection. Hepatic abscess
is therefore a possible event after RF treatment and a
few deaths have occurred, mostly due to peritonitis
and inadequate aseptic technique [49]. Special care
should be taken in patients with diabetes or biliary-
enteric communication.
Risk minimization is achieved after careful evalua-
tion of the patient’s medical condition, immune
function, surgical history and liver volume relative to
tumor burden. Planning the most appropriate RFA
approach is also crucial in order to avoid possible
technique-related complications.
The major drawback of RFA is the unpredictable
necrosis rate due to the lack of correlation between
image changes and extent of ablation. Even histology
with special histochemistry techniques (reduced ni-
cotinamide adenine dinucleotide staining) cannot
reliably predict the viability of individual cells at the
advancing edge of the ablation zone. Thus RFA is an
alternative option to resection for small HCC in
nonsurgical candidates since resection remains the
‘gold standard’ treatment worldwide. Randomized
controlled studies are needed to evaluate the potential
benefit of RFA over other local ablative therapies and
surgical resection.
Bloodless liver resection
Blood loss during liver resection remains one of the
most important factors affecting postoperative mor-
bidity and mortality [50]. As a result, multiple
approaches have evolved to reduce bleeding during
the parenchymal transection phase. Recent efforts
have aimed to use vessel-sealing devices based on RF
energy for parenchymal transection to accomplish
bloodless liver resection combined with less intrao-
perative ischemia (no inflow occlusion).
In an attempt to facilitate liver resection Habbib
[51] popularized his method of hepatectomy using
RF-assisted coagulation. Multiple insertions of the
RF needle close to the surgical margin create a
bloodless field. The needle is placed in the parench-
yma under US guidance. RF should last 60 seconds to
obtain a zone of tissue necrosis with a radius of at least
1 cm and a depth of 3 cm. After complete coagulation
is achieved the probe is placed 2 cm away from the
point of previous application. Once RF thermal
ablation has been completed along the resection
line, the parenchymal transection can be performed
with the use of a common scalpel.
The Cool-Tip radiofrequency device (Radionics,
Tyco Healthcare) uses RF energy transmitted through
the electrode to the adjacent liver parenchyma causing
ion vibration with heat production. In fact the device
is able to achieve both necrosis of the liver tissue and
sealing of blood vessels up to 3 mm in diameter by
collagen fusion [52]. The saline circuit at the tip of the
RF needle offers better ion agitation and avoids
charring with eschar formation. The device takes
advantage of its unique function to enhance heat
conduction with a better tumoricidal effect.
These findings lend important functional support
to the concept of bloodless liver resection in cirrhotic
patients and demanding segmentectomies (segment
VIII, central hepatectomy, etc.). Of note, the demar-
cation line produced by the Cool-Tip device is further
extended in the liver remnant, increasing the surgical
margin. This effect is useful in cases with poor liver
function where limited resections are indicated.
The Tissuelink Monopolar Floating Ball device
(TMFB) [53] uses the same principles to seal vascular
structures, creating a bloodless field, and seems pro-
mising due to the low cost, since is compatible with
most electrosurgical generators. Latteri et al. [53]
reported their experience with TMFB in nine con-
secutive patients. They demonstrated minimal blood
loss (range 50300 ml) with an average resection time
of 20 minutes (range 1055 minutes). While the data
are encouraging, only two major liver resections were
performed. Although TMFB is effective, its use is
limited as a transection instrument only, because the
floating ball cannot insert in the parenchyma to ablate
other lesions further to the segment resected. In this
situation of a combined resectionablation procedure
Radionics proved to be more flexible and effective.
The Agia Olga experience
Our group performs liver resection using Radionics as
a cutting device for parenchymal transection. The
protocol was initiated 1 year ago and has been actively
pursued for malignant and benign tumors of the liver.
Once the type of hepatectomy is decided upon based
on the visual exploration and US examination of the
liver, the line of resection is marked by diathermy on
Figure 5. Contrast-enhanced CT scan after percutaneous CT-
guided RFA, demonstrates a left liver lobe subcapsular hematoma.
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the liver surface. Inflow occlusion was never used in
our series.
Next the Cool-tip RF (Radionics, Burlington, Tyco
Healthcare, MA, USA) with a single 3-cm long needle
is applied in the parenchyma. The needle is cooled by
circulating cold saline and is coupled to a 480 kHz
generator. RFA should last 60 seconds to obtain a
zone of tissue necrosis with a radius of 3 cm. Once RF
ablation has been completed a common scalpel is
used to divide the tissue. In case of bleeding addi-
tional application of the needle can be used to achieve
hemostasis. The probe then moves following the
transection line and a new application is initiated to
separate liver tissue.
Although this was not a comparative study, there
was an apparent effect on the resection time (median
45 minutes). We noted that the technique is faster
than the traditional methods, primarily because it
facilitates oozing control. Most patients underwent
minor resections (15) and 5 had major resections with
minimal blood loss (median 150 ml). No blood
transfusion was required nor have we noted any
difference in the estimated blood loss and the under-
lying liver disease, albeit eight patients were cirrhotic.
There was also a sense that RF-assisted resection
caused less liver enzyme elevation compared with the
traditional techniques applied with inflow occlusion.
The 30-day mortality rate was zero. Procedure-related
complications included a bile leak (which was man-
aged conservatively and regressed after 5 days) in a
patient with HCC and underlying cirrhosis who
underwent segment V-VI resection at the beginning
of our study. It is possible that sealing of biliary
radicles requires more time than vessels.
The future
Since the clinical application of RF continues to be a
possible alternative to liver resection in the manage-
ment of HCC, it is useful to consider specific
questions regarding how it might be effective to
achieve similar results.
RF equipment. The development of advanced RF
devices to create homogeneous tissue ablation in a
predictable manner with few sessions requires the
combined efforts of technology and science. New
equipment comprising multiple RF needles to create a
bloodless field during resection retains the benefit of
minimal blood loss along with a shorter operating
time. This concept, if brought to clinical reality, could
have the potential to resect liver tumors with low
morbidity.
Laparoscopic liver resection using RF. While it has been
difficult to translate experimental success (from stu-
dies in pigs using RF bloodless liver resection) to the
clinical arena, there have been anecdotal reports
where this approach has been implemented in hu-
mans. These reports lend important functional sup-
port to the concept of minimally invasive techniques
in liver surgery with low morbidity in the setting of
cirrhosis and poor performance status.
The role of real-time imaging. Expected advances in
hardware and software, including 3D imaging, will
permit improvements in accurate lesion targeting,
better evaluation of residual disease and earlier
detection of tumor recurrence. PET will also play a
crucial role in the future, in differentiating functioning
from nonfunctioning residual ‘mass’ after ablation
treatment.
The ‘Holy Grail’ of liver surgery in the management of
HCC. As such, the potential to prevent tumor
recurrence using new adjuvant protocols after the
resection-ablation process.
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